Sotera Health Company · NASDAQ:SHC
Sotera Health — Q2 2026 Earnings Presentation
26 slides from Sotera Health's earnings presentation, Aug 6, 2026
Slide 1: Second-Quarter and Year-to-Date 2026 Earnings Results
Safeguarding Global Health® Second-Quarter and Year-to-Date 2026 Earnings Results August 6, 2026 © 2026 Sotera Health Company | All Rights Reserved.
Slide 2: Cautionary Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures
Cautionary Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures Unless expressly indicated or the context requires otherwise, the terms “Sotera Health,” “Company,” “we,” “us,” and “our” in this presentation refer to Sotera Health Company, a Delaware corporation, and, where appro
Slide 3: Speakers
Speakers Michael B. Petras, Jr. Executive Chairman of the Board Alton Shader Chief Executive Officer Jonathan M. Lyons Senior Vice President and Chief Financial Officer © 2026 Sotera Health Company | All Rights Reserved. 2
Slide 4: Second-Quarter Performance
Second-Quarter Performance “We delivered another strong quarter, with high-single- digit growth, reflecting focused execution across all three of our business units. Since joining the Company, I have been impressed by the dedication of our teams, the trust our customers place in us and the industry-
Slide 5: Q2 2026 Highlights
Q2 2026 Highlights (1) Net Performance Revenues 9.2%; 8.0% CC (2)(3) Delivered strong, high-single-digit top- and bottom-line CC growth Expanded Adjusted EBITDA margin to nearly 52% Sterigenics: 7.0% CC revenue growth; segment income margin improvement of 53 basis points Nordion: 16.7% CC re
Slide 6: Consolidated Financial Performance
Consolidated Financial Performance $ In millions, except Adjusted EPS and Adjusted EBITDA margin Second Quarter YTD +9.2% / +8.0% CC +9.6% / +7.4% CC $321 $601 Revenue $294 $549 2025 2026 2025 2026 +10.0% / +8.7% CC +10.2% / +7.9% CC $166 $300 $273 Adjusted EBITDA $151 51.2% 51.6% 49.7% 49.9% 2025 2
Slide 7: Sterigenics Financial Performance
Sterigenics Financial Performance $ In millions Second Quarter YTD Net Revenues +8.6% / +7.0% CC Net Revenues +9.1% / +6.6% CC Segment Income +9.6% / +7.9% CC Segment Income +9.6% / +7.0% CC $212 $398 $195 $365 $118 $215 $108 $196 55.3% 55.8% 53.7% 53.9% 2025 Revenue Segment Income 2026 2025 Revenue
Slide 8: Nordion Financial Performance
Nordion Financial Performance $ In millions Second Quarter YTD Net Revenues +15.8% / +16.7% CC Net Revenues +21.6% / +20.8% CC Segment Income +19.2% / +20.6% CC Segment Income +26.4% / +26.0% CC $91 $49 $42 $75 $28 $52 $23 $41 55.3% 56.9% 54.5% 56.7% 2025 Revenue Segment Income 2026 2025 Revenue Seg
Slide 9: Nelson Labs Financial Performance
Nelson Labs Financial Performance $ In millions Second Quarter YTD Net Revenues +6.3% / +5.4% CC Net Revenues +2.9% / +0.9% CC Segment Income +0.6% / -0.6% CC Segment Income -4.9% / -7.4% CC $61 $109 $113 $57 $20 $20 $36 $34 34.2% 32.4% 32.9% 30.4% 2025 Revenue Segment Income 2026 2025 Revenue Segme
Slide 10: Liquidity, Net Leverage and Investments
Liquidity, Net Leverage and Investments $ In millions $937 $948 $687 $592 $592 $410 • Continued strong cash and liquidity position Liquidity (1) • No outstanding borrowings on revolving line of credit $277 $345 $357 12/31/24 12/31/25 6/30/26 Unrestricted Cash Revolver Availability 3.7x Net 3.2x 3.0x
Slide 11: 2026 Outlook
2026 Outlook © 2026 Sotera Health Company | All Rights Reserved. 10
Slide 12: Raising Full-year 2026 Outlook
Raising Full-year 2026 Outlook May 5th Outlook August 6th Outlook $1,233M to $1,251M $1,236M to $1,254M Net Revenues +6.00% to 7.50% +6.25% to 7.75% +5.00% to 6.50% CC +5.25% to 6.75% CC $632M to $641M $634M to $643M Adjusted EBITDA +6.50% to 8.00% +6.75% to 8.25% +5.50% to 7.00% CC +5.75% to 7.25%
Slide 13: Additional 2026 Outlook Items
Additional 2026 Outlook Items (1) • Expected full-year foreign exchange benefit of 100 basis points; Foreign currency expected to be a slight headwind in Q3 Outlook • Total company pricing within our long-term 3% - 4% range Highlights • Net Leverage Ratio expected to improve • Outlook assumes no M&A
Slide 14: Corporate Overview
Corporate Overview © 2026 Sotera Health Company | All Rights Reserved. 13
Slide 15: Safeguarding Global Health®
Safeguarding Global Health® Global customer base in over Over 3,000 employees Provide end-to-end Integrated global network of 50 countries solutions for our customers 63 facilities located in in highly-regulated markets 13 countries Customers include 40+ of top 50 medical device companies, Customer
Slide 16: Our Crucial Role in the Healthcare Supply Chain
Our Crucial Role in the Healthcare Supply Chain R&D, materials Pre-FDA filing tests Product Sterilization Quality control Distribution and packaging and clinical trials manufacturing tests optimization ✓✓ ✓✓ ✓ ✓✓✓ ✓✓ ✓ ✓ ✓ © 2026 Sotera Health Company | All Rights Reserved. 15
Slide 17: Three Integrated Businesses Supporting the Global Healthcare Supply Chain
Three Integrated Businesses Supporting the Global Healthcare Supply Chain Global leader in comprehensive World’s Largest Provider of Global leader in microbiological sterilization solutions Cobalt-60 sealed sources and analytical lab testing 2,000+ Providing 2,000+ customers Customers(1) (1) peace o
Slide 18: Our Company's Key Priorities
Our Company’s Key Priorities 1 2 3 4 Excellence in Win in growth Driving Disciplined serving our markets operational capital customers with excellence to deployment end-to-end enhance free solutions cash flow Strong Execution to Generate Value for Our Stakeholders © 2026 Sotera Health Company | All
Slide 19: Global Leader Positioned for Sustainable Growth
Global Leader Positioned for Sustainable Growth © 2026 Sotera Health Company | All Rights Reserved. 18
Slide 20: Appendix
Appendix © 2026 Sotera Health Company | All Rights Reserved. 19
Slide 21: Non-GAAP Financial Measures
Non-GAAP Financial Measures (unaudited) (dollars in thousands, except per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Net income (loss) $ 53,643 $ 7,962 $ 80,232 $ (5,298) Amortization of intangible assets 5,563 11,924 11,165 30,598 Share-based compensati
Slide 22: Non-GAAP Financial Measures (continued)
Non-GAAP Financial Measures (continued) a) Represents share-based compensation expense related to employees and Non-Employee Directors. b) Represents the write-off of unamortized debt issuance costs and discounts, as well as certain other costs incurred related to the Refinancing Term Loans and the
Slide 23: Non-GAAP Financial Measures (continued)
Non-GAAP Financial Measures (continued) (unaudited) (dollars in thousands, except per share amounts) Twelve months Year end December 31, ended June 30, 2024 2025 2026 Net income $ 44,398 $ 77,949 $ 163,479 Amortization of intangible assets 79,377 41,798 22,365 Share-based compensation(a) 36,896 31,0
Slide 24: Non-GAAP Financial Measures (continued)
Non-GAAP Financial Measures (continued) a) Represents share-based compensation expense related to employees and Non-Employee Directors. b) Represents the write-off of unamortized debt issuance costs and discounts, as well as certain other costs incurred related to the refinancing activity for the Te
Slide 25: Non-GAAP Financial Measures (continued)
Non-GAAP Financial Measures (continued) (unaudited) (dollars in thousands) As of December 31, As of June 30, 2024 2025 2026 Current portion of long-term debt $ 14,803 $ 13,973 $ 13,923 Long-term debt less current portion 2,208,100 2,126,724 2,125,534 Current portion of finance leases 2,923 3,465 3,7
Slide 26: Non-GAAP Financial Measures Definitions
Non-GAAP Financial Measures Definitions • Adjusted Net Income is defined as net income (loss) before amortization and certain other adjustments that we do not consider in our evaluation of our ongoing operating performance from period to period. • Adjusted EBITDA is defined as Adjusted Net Income be
Sotera Health Company — Q2 2026 Earnings Presentation on 6ix